Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to assets ratio high or low?
The debt to assets ratio of 1.38% is in line with its 5-year average of 1.26%, around the middle of its 5-year range (0.16%–2.82%).
As of the fiscal period ended Tuesday, June 30, 2026. 16.22% below its 12-month average of 1.65%.
Reported quarterly debt to assets ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 1.38%.
DEBT TO ASSETS RATIO
1.38%
DEBT TO ASSETS RATIO AVG TTM
1.65%
DEBT TO ASSETS RATIO AVG 3Y
1.76%
DEBT TO ASSETS RATIO AVG 5Y
1.26%
DEBT TO ASSETS RATIO AVG 10Y
1.02%
DEBT TO ASSETS RATIO AVG 15Y
N/A
DEBT TO ASSETS RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
-16.22%
CURRENT VS 3Y AVG
-21.33%
CURRENT VS 5Y AVG
+9.88%
CURRENT VS 10Y AVG
+35.57%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.09%
median of 874 covered companies
CURRENT VS SECTOR MEDIAN
+1438.60%
vs the sector median at left
Moleculin Biotech, Inc.
Market Cap
$2.38M
Debt to Assets Ratio
1.38%
TTM Avg
1.65%
3Y Avg
1.76%
5Y Avg
1.26%
Market Cap
$2.38M
Debt to Assets Ratio
0.01%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$2.37M
Debt to Assets Ratio
0.18%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$2.32M
Debt to Assets Ratio
0.00%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$2.54M
Debt to Assets Ratio
0.19%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$2.14M
Debt to Assets Ratio
0.50%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | DEBT TO ASSETS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Moleculin Biotech, Inc. (MBRX) | $2.38M | 1.38% | 1.65% | 1.76% | 1.26% |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH)vs › | $2.38M | 0.01% | N/A | N/A | N/A |
| Onconetix, Inc. (ONCO)vs › | $2.37M | 0.01% | N/A | N/A | N/A |
| FibroBiologics, Inc. Common Stock (FBLG)vs › | $2.37M | 0.18% | N/A | N/A | N/A |
| Creative Medical Technology Holdings, Inc. (CELZ)vs › | $2.32M | 0.00% | N/A | N/A | N/A |
| Jaguar Health, Inc. (JAGX)vs › | $2.44M | 0.49% | N/A | N/A | N/A |
| bioAffinity Technologies, Inc. (BIAF)vs › | $2.54M | 0.19% | N/A | N/A | N/A |
| Nuwellis, Inc. (NUWE)vs › | $2.56M | 0.02% | N/A | N/A | N/A |
| Vivos Therapeutics, Inc. (VVOS)vs › | $2.14M | 0.50% | N/A | N/A | N/A |
| GeoVax Labs, Inc. (GOVX)vs › | $2.13M | 0.07% | N/A | N/A | N/A |
Debt/Assets
1.4%
Debt/Equity
0.03
Current Ratio
0.94
Interest Coverage
N/A
Formula: Debt/Assets = Total Debt / Total Assets × 100
Debt/Assets vs Debt/Equity:
Industry context matters: Capital-intensive industries (utilities, real estate) typically have higher Debt/Assets ratios than tech companies.
Debt/Assets ratio shows what percentage of a company's assets are financed by debt. Compare the current value with the historical chart and peer group to understand leverage over time.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO ASSETS RATIO |
|---|---|
| 2026-06-30 | 1.38% |
| 2026-03-31 | 1.40% |
| 2025-12-31 | 1.62% |
| 2025-09-30 | 1.92% |
| 2025-06-30 | 1.95% |
| 2025-03-31 | 2.14% |
| 2024-12-31 | 2.82% |
| 2024-09-30 | 2.16% |
| 2024-06-30 | 2.08% |
| 2024-03-31 | 1.81% |
| 2023-12-31 | 1.50% |
| 2023-09-30 | 1.48% |
| 2023-06-30 | 0.62% |
| 2023-03-31 | 0.60% |
| 2022-12-31 | 0.79% |
| 2022-09-30 | 0.73% |
| 2022-06-30 | 0.66% |
| 2022-03-31 | 0.16% |
| 2021-12-31 | 0.19% |
| 2021-09-30 | 0.21% |
| 2021-06-30 | 0.24% |
| 2021-03-31 | 0.25% |
| 2020-12-31 | 0.95% |
| 2020-09-30 | 1.12% |
| 2020-06-30 | 1.05% |
| 2020-03-31 | 1.39% |
| 2019-12-31 | 1.50% |
| 2019-09-30 | 1.33% |
| 2019-06-30 | 0.54% |
| 2019-03-31 | 1.00% |
| 2018-12-31 | 0.00% |
| 2018-09-30 | 0.00% |
| 2018-06-30 | 0.00% |
| 2018-03-31 | 0.00% |
| 2017-12-31 | 0.00% |
| 2017-09-30 | 0.00% |
| 2017-06-30 | 0.00% |
| 2017-03-31 | 0.53% |
| 2016-12-31 | 1.81% |
| 2016-09-30 | 1.69% |
| 2016-06-30 | 2.24% |
| 2016-03-31 | 212.32% |
| 2015-09-30 | 226.57% |
